Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report fourth quarter and full-year 2012 financial results after the close of the market on Thursday, March 28, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) disorders. All of the Company's product candidates have been discovered using its proprietary chemistry technology platform, MATCHâ„¢ (Macrocyclic Template Chemistry), which enables the construct of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. By leveraging MATCHâ„¢, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical need, and continues to seek collaborative drug discovery partnerships.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here